title: The effect of tenoxicam on intraperitoneal adhesions and prostaglandin E2 levels in mice.
abstract: We determined whether tenoxicam administered intraperitoneally in the preoperative period had an effect on the development of postoperative intraabdominal adhesions (IAA). For this purpose, 100 albino mice were divided into four random groups. Mice in Group 1 were given only 1 mL of 0.9% NaCl intraperitoneally, whereas in Group 2, 1 mL of tenoxicam (150 microg = 5 mg/kg) was administered. After the induction of anesthesia, a median laparotomy was performed, and the bowels were traumatized by touching them with powdered gloves before the incision was closed in Groups 3 and 4. Intraperitoneal tenoxicam was administered to mice in Group 4 after skin closure. All mice were killed after 14 days to determine macroscopic and microscopic IAA; prostaglandin E2 levels were also measured. Postoperative evaluation revealed a reduced IAA formation and a parallel decrease in tissue prostaglandin E2 levels in Group 1 and 2 mice. We conclude that intraperitoneal tenoxicam decreased IAA formation with no peritoneal reaction in the postoperative period.
  
  
  CONCLUSIONS
  Postoperative intraabdominal adhesions can cause intestinal obstruction, pelvic pain, or infertility. In this study, we showed that intraperitoneally administered tenoxicam decreases tissue prostaglandin E2 levels and intraabdominal adhesions in mice.
authors: Department of Anesthesiology, School of Medicine, Hacettepe University, Ankara, Turkey.
authors: B
authors: B
authors: Celebioglu
authors: N R
authors: NR
authors: Eslambouli
authors: E
authors: E
authors: Olcay
authors: S
authors: S
authors: Atakan
mesh_terms: D000005:Abdomen / Q000601:surgery; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D015232:Dinoprostone / Q000378:metabolism*; D005260:Female; D007082:Ileum / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D010532:Peritoneal Diseases / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D000267:Tissue Adhesions / Q000473:pathology / Q000517:prevention & control
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D015232:Dinoprostone; C032801:tenoxicam